IBA cooperates with Philips to create proton therapy centers

IBA Group, a leader in advanced cancer diagnosis and therapy technologies and Royal Philips Electronics, announced they have entered into an agreement to create state of the art patient-centric proton therapy centers.

Photo: IBA cooperates with Philips to create proton therapy centers
Photo: IBA cooperates with Philips to create proton therapy centers

IBA and Philips presented their plans together at the European Society of Therapeutic Radiology and Oncology (ESTRO) Anniversary Congress in London, UK, 8-12 May 2011, and the Particle Therapy Co-Operative Group (PTCOG) conference in Philadelphia, Penn., USA, 8-14 May 2011.

This cooperation is an important milestone in creating meaningful oncology solutions for caregivers, patients and their families who are in a very stressful situation. The complete center design is based on a deep understanding of all emotional and physical aspects of patient care. From the moment they enter the center up to their final treatment, the patient is surrounded by light, image and sound making the treatment experience as soothing and transparent as possible, while helping caregivers to work more efficiently.

The IBA-Philips ‘turnkey’ proton center concept is the first of its kind, and is initially being developed for the Middle East market, with subsequent plans to expand its use globally. Named ‘Proteus TK2’, the IBA-Philips center design encompasses all elements necessary to build a complete proton therapy center. This includes the building exterior and interior architecture, two IBA proton therapy treatment rooms, Philips Ambient Experience Design solutions, Philips CT, CT SIM, MRI imaging solutions and patient monitoring equipment.

“This joint approach combines the strength of both companies that believe in a true people-focused solution, which makes this concept extremely attractive for those wanting to add proton therapy to their cancer fighting therapies” says Pierre Mottet, Chief Executive Officer of IBA.

Dr. Eric Silfen, Chief Medical Officer, Philips Healthcare adds: “We are very proud to work together with IBA Group, a global leader in the proton technology market. Philips is committed to simplifying oncology care for a patient group that is still growing around the world”.

10.05.2011

Read all latest stories

Related articles

Photo

Going digital

How digital pathology is shaping the future of precision medicine

In recent years, technological and regulatory advances have made digital pathology a viable alternative to the conventional microscope. The obtention of a digital replica of the traditional glass…

Photo

Solution for pediatric assessment

Ultrasound: A gentler approach to imaging children

Royal Philips announced the ultimate ultrasound solution for pediatric assessment, the latest addition for its Philips Ultrasound System (EPIQ Elite). The new ultrasound solution provides clinicians…

Photo

Digital PET imaging

Digital Photon Counting improves diagnostic accuracy

Built as the first commercially available scanner to deliver truly digital PET, the Vereos PET/CT, from Philips, offers revolutionary Digital Photon Counting technology. The science behind this…

Related products

IBA Dosimetry – 2-part PMMA CT-Phantom

Testing Devices

IBA Dosimetry – 2-part PMMA CT-Phantom

IBA Dosimetry GmbH
IBA Dosimetry – 3-part PMMA CT-Phantom

Testing Devices

IBA Dosimetry – 3-part PMMA CT-Phantom

IBA Dosimetry GmbH
IBA Dosimetry – DIGI-13

Testing devices

IBA Dosimetry – DIGI-13

IBA Dosimetry GmbH
IBA Dosimetry – Dosimax plus A (HV)*

Testing Devices

IBA Dosimetry – Dosimax plus A (HV)*

IBA Dosimetry GmbH
IBA Dosimetry – Dosimax plus I

Testing Devices

IBA Dosimetry – Dosimax plus I

IBA Dosimetry GmbH
IBA Dosimetry – DSA Test Device

Testing Devices

IBA Dosimetry – DSA Test Device

IBA Dosimetry GmbH